# Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

> **NCT03073473** · — · TERMINATED · sponsor: **Cota Inc.** · enrollment: 40 (actual)

## Conditions studied

- Pancreatic Cancer
- Metastatic Breast Cancer
- Metastatic Lung Cancer
- Metastatic Colon Cancer
- Metastatic Melanoma
- Metastatic Prostate Cancer

## Interventions

- **DIAGNOSTIC_TEST:** NantHealth GPS Cancer Test

## Key facts

- **NCT ID:** NCT03073473
- **Lead sponsor:** Cota Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-28
- **Primary completion:** 2018-06-13
- **Final completion:** 2018-06-13
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2018-07-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03073473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03073473, "Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03073473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*